This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage

This study has been completed.
Information provided by (Responsible Party):
Abbott ( Abbott Products ) Identifier:
First received: September 11, 2005
Last updated: August 25, 2011
Last verified: August 2011
The purpose of this clinical study is to demonstrate the shift from inflammatory cytokines to non-inflammatory cytokines in women suffering from habitual abortion treated with dydrogesterone (Duphaston).

Condition Intervention Phase
Recurrent Miscarriage Drug: Dydrogesterone Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Oral Dydrogesterone Treatment During the First Trimester of Pregnancy in Women With Recurrent Miscarriage: A Double-Blind, Prospectively Randomized, Placebo-Controlled, Parallel Group Trial

Resource links provided by NLM:

Further study details as provided by Abbott ( Abbott Products ):

Primary Outcome Measures:
  • Cytokine ratio IFN/IL-10 [ Time Frame: 14 weeks treatment after diagnosed pregnancy (week of gestation 4 to 18) ]

Secondary Outcome Measures:
  • Exploratory analysis of pregnancy outcome by monitoring biochemical and clinical pregnancy parameters, weekly evaluation of serum progesterone [ Time Frame: First trimester of pregnancy ]

Enrollment: 71
Study Start Date: September 2003
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Dydrogesterone
20 mg/day, oral
Placebo Comparator: 2 Drug: Placebo


Ages Eligible for Study:   18 Years to 38 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Women with a history of idiopathic recurrent miscarriage, based on a documented history of at least three spontaneous consecutive miscarriages before 20 weeks gestation with the same partner Exclusion Criteria
  • Any verifiable cause of the recurrent miscarriages apart from luteal phase defect (e.g. systemic lupus erythematosus [SLE], infections with chlamydia or mycoplasma)
  • Any gynecological neoplasias or anatomical abnormalities that oppose pregnancy
  • Concurrent infertility treatment/superovulation protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00193674

Site Reference ID/Investigator# 61182
Vienna, Austria, 1090
Site Reference ID/Investigator# 61183
Poznan, Poland, 60-535
Site Reference ID/Investigator# 61184
Szczecin, Poland, 72-010
Sponsors and Collaborators
Abbott Products
Study Director: Guenter Krause, MD Abbott Products
  More Information

Responsible Party: Abbott Products Identifier: NCT00193674     History of Changes
Other Study ID Numbers: S102.3.116
Study First Received: September 11, 2005
Last Updated: August 25, 2011

Keywords provided by Abbott ( Abbott Products ):
Unexplained recurrent miscarriage

Additional relevant MeSH terms:
Abortion, Spontaneous
Abortion, Habitual
Pregnancy Complications
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on June 23, 2017